Skip to main content

Advertisement

Table 4 Median change of circulating biomarkers.

From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

    Baseline Six weeks Change   
Variable Treat. N Obs Median IQR Median IQR Median IQR Contrast1 P
Fibrinogen P 25 312.0 (273.0 to 340.0) 333.5 (276.0 to 354.0) 4.5 (-19.0 to 24.0) T vs. R 0.02
mg/dL R 50 301.0 (254.0 to 334.0) 260.0 (230.0 to 288.0) -29.5 (-61.0 to -5.0) T + R vs. P 0.01
  T 50 286.0 (247.0 to 319.0) 285.0 (243.0 to 312.0) -2.0 (-20.0 to 12.0)   
Antithrombin P 25 102.0 (98.0 to 109.0) 99.0 (93.0 to 104.0) -1.0 (-5.0 to 4.0) T vs. R 0.75
% R 50 103.0 (98.0 to 108.0) 94.0 (90.0 to 101.0) -8.0 (-11.0 to -1.0 T + R vs. P 0.02
  T 50 106.0 (98.0 to 114.0) 100.0 (92.0 to 106.0) -7.0 (-16.0 to -1.0)   
CRP P 25 0.6 (0.3 to 2.8) 0.8 (0.3 to 3.3) 0.0 (-0.1 to 0.6) T vs. R 0.12
mg/dL R 50 1.0 (0.5 to 1.9) 0.6 (0.4 to 1.3) -0.3 (-0.7 to 0.1) T + R vs. P 0.21
  T 50 0.7 (0.4 to1.2) 0.8 (0.4 to 1.3) 0.1 (-0.3 to 0.3)   
Cholesterol P 25 199.0 (185.0 to 224.0) 225.5 (197.0 to 244.0) 13.5 (1.0 to 33.0) T vs. R 0.30
mg/dL R 50 199.5 (179.0 to 222.0) 192.0 (168.0 to 215.0) -7.0 (-23.0 to 5.0) T + R vs. P <.0001
  T 50 201.5 (180.0 to 220.0) 188.5 (171.0 to 200.0) -12.0 (-18.0 to 0.0)   
CTX ng/mL P 25 0.3 (0.2 to 0.4) 0.3 (0.2 to 0.3) 0.0 (-0.1 to 0.0) T vs. R 0.05
  R 50 0.3 (0.2 to 0.4) 0.3 (0.2 to 0.4) 0.0 (0.0 to 0.1) T + R vs. P 0.58
  T 50 0.3 (0.2 to 0.4) 0.3 (0.2 to 0.4) 0.0 (-0.1 to 0.0)   
Osteocalcin P 25 16.9 (13.4 to20.3) 16.5 (13.1 to 22.5) -0.5 (-1.9 to 2.2) T vs. R 0.39
ng/mL R 50 17.9 (13.8 to 22.5) 16.8 (13.4 to 20.8) -1.7 (-3.5 to 1.1) T + R vs. P 0.32
  T 50 16.0 (61.98 to 165.5) 15.3 (12.5 to 20.2) -0.7 (-2.0 to 1.0)   
  1. 1Change adjusted for baseline. CRP, C-reactive protein; CTX, C-telopeptide; IQR, interquartile range; P, placebo; R, raloxifene 60 mg/day; T, tamoxifen 10 mg/week.